Stories

In today’s rapidly evolving treatment landscape the approval of a medicine is no longer the finish line; it’s just the beginning. Real world evidence (RWE), post-hoc analyses and structured Phase IV studies all offer new opportunities for scientific learning. At Ipsen, we’re committed to pursuing the unanswered questions, generating robust evidence that goes beyond medicine development, which provides broader long-term evidence-based perspectives for the communities we serve.

At Ipsen, medical insights are not an end in themselves. They help us better understand the reality experienced by patients, healthcare professionals and health systems so we can make better decisions across our organisation.

For too long, modern medicine has treated diseases as if they were uniform, defined by a label rather than by their underlying biology. Today, we have an unprecedented ability to interrogate the molecular drivers that shape each person’s cancer, and in doing so, we’re transforming how we diagnose, develop and deliver the medicines that matter most.